What is the therapeutic effect of osimertinib combined with cabozantinib? Research progress of combined drugs

Research on the combined use of Osimertinib (Osimertinib) and Cabozantinib (Cabozantinib) Research mainly focuses on the treatment of non-small cell lung cancer (NSCLC), especially for patients with advanced or metastatic lung cancer with EGFR mutations. The two drugs act on different signaling pathways, and their combined use may help enhance the efficacy and overcome the limitations of monotherapy.

1. The mechanism of action of osimertinib: Osimertinib is a third-generation EGFR-TKI (tyrosine kinase inhibitor), specifically used to treat patients with EGFR T790M mutated non-small cell lung cancer. It can selectively inhibit the kinase activity of EGFR mutants, inhibit the proliferation and growth of tumor cells, and has strong anti-tumor activity.

2. Mechanism of action of cabozantinib: Caboozantinib is a multi-target tyrosine kinase inhibitor that mainly inhibits tumor angiogenesis, tumor growth and metastasis by inhibiting multiple pathways such as VEGFR, MET and AXL. Its influence on the tumor microenvironment helps inhibit tumor immune evasion and drug resistance mechanisms.

3. Potential and research progress of combination therapy: Research on the combination of osimertinib and cabozantinib is still in the clinical trial stage. Preliminary studies show that the combination of these two drugs has potential in the treatment of patients with EGFR mutation-positive non-small cell lung cancer, especially those with brain metastases. Osimertinib targets EGFR mutations, while cabozantinib enhances the inhibitory effect on the tumor microenvironment and reduces the escape ability of tumor cells through the inhibition of multiple pathways. Additionally, combination therapy may help overcome resistance to monotherapy, particularly when patients with EGFR-mutant cancers develop resistance to osimertinib monotherapy.

4. Clinical research results and challenges: Existing clinical research results show that the treatment regimen of osimertinib combined with cabozantinib has achieved good results in some patients, especially for some EGFRTumor growth control is better in patients with advanced mutations. However, the management of side effects of combined drugs is still a challenge, and patients may suffer from more complex side effects, such as abnormal liver function, gastrointestinal discomfort, etc. Therefore, doctors need to closely monitor the patient's physical condition during treatment and adjust the dosage and treatment plan.

Generally speaking, the combination treatment of osimertinib and cabozantinib shows certain promise in non-small cell lung cancer, especially in advanced cases with EGFR mutations, but more clinical data and long-term observation are still needed to verify its efficacy and safety.

Reference:https://en.wikipedia.org/wiki/Cabozantinib